Study: NCT01620216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antitumor Drug Screening Assay
Description: Undergo pre clinical kinase inhibitor activity screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antitumor Drug Screening Assay
Description: Undergo pre clinical kinase inhibitor activity screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antitumor Drug Screening Assay
Description: Undergo pre clinical kinase inhibitor activity screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antitumor Drug Screening Assay
Description: Undergo pre clinical kinase inhibitor activity screening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO